Additionally, Weng et al. reported that lenvatinib enhances the efficacy of RT in HCC by inhibiting the Src/STAT3/NF-κB pathway, which mediates epithelial-mesenchymal transition and metastasis, leading to a synergistic effect [32]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.